Related Experiment Video

Updated: Apr 28, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

15.4K

Reversal of target-specific oral anticoagulants

Deborah M Siegal1, Adam Cuker2

  • 1Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Drug Discovery Today
|June 1, 2014
PubMed

Insights

Target-specific oral anticoagulants (TSOACs) offer safe anticoagulation but lack reversal agents. Current evidence for reversing TSOACs is limited, necessitating clinical studies on bleeding outcomes.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Target-specific oral anticoagulants (TSOACs) are widely used for thrombosis prevention and treatment.
  • TSOACs, including dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, offer advantages over vitamin K antagonists (VKAs).
  • A critical limitation of TSOACs is the absence of specific reversal agents.

Purpose of the Study:

  • To review existing evidence on reversing TSOACs using nonspecific and specific agents.
  • To highlight limitations in the current body of evidence for TSOAC reversal.
  • To emphasize the need for clinical trials evaluating reversal agents in patients experiencing TSOAC-associated bleeding.

Main Methods:

  • Literature review of studies on TSOAC reversal agents.
  • Analysis of evidence from human volunteer studies, animal models, and in vitro experiments.
  • Discussion of limitations in current research.

Main Results:

  • Evidence for TSOAC reversal is primarily derived from non-clinical studies.
  • Nonspecific and specific reversal agents have been investigated.
  • The safety and efficacy of these agents in real-world clinical scenarios remain largely unevaluated.

Conclusions:

  • Current evidence on TSOAC reversal agents is limited and derived from preclinical and volunteer studies.
  • Further research is required to establish the safety and efficacy of reversal agents in patients with TSOAC-associated bleeding.
  • Clinical outcome studies are essential to guide the management of TSOAC-related bleeding events.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Antidotes01:17

Antidotes

Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
1.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157